Chardan: Sell Axovant Sciences, RVT-101 Market Pricing Is 'Highly Irrational'

By: via Benzinga
In a report published Thursday, Chardan Capital analyst Gbola Amusa initiated coverage of Axovant Sciences Ltd (NYSE: AXON) with a Sell ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.